VIRALYTICS LTD. 
By
Viralytics Limited (ASX: VLA, OTC: VRACY):Viralytics Limited (ASX:VLA, OTC:VRACY) will present at two prominent US healthcare investment conferences next week.
CEO, Dr Malcolm McColl, will present on March 10 at the 26th Annual ROTH Investment Conference in Dana Point, California. The ROTH conference is one of the largest of its kind in the US with approximately 3,000 attendees including 1,000 from the global investment community.
On March 12 Dr McColl will present at the Bernstein Emerging Biotech Conference in Snowbird, Utah. Viralytics is the only Australian company invited to present at this exclusive conference, with an audience comprising many of the leading US institutional investors in the biotech and healthcare field.
Dr McColl said: "Viralytics' profile among US institutional healthcare investors is rapidly ascending. These are both very significant conferences in which we will outline recent accomplishments and the company's strategic pathway. Following our successful capital raise we now have an impressive base of international institutional investors."
The presentation from Dr McColl will highlight recent developments and future clinical and business plans including:
CEO, Dr Malcolm McColl, will present on March 10 at the 26th Annual ROTH Investment Conference in Dana Point, California. The ROTH conference is one of the largest of its kind in the US with approximately 3,000 attendees including 1,000 from the global investment community.
On March 12 Dr McColl will present at the Bernstein Emerging Biotech Conference in Snowbird, Utah. Viralytics is the only Australian company invited to present at this exclusive conference, with an audience comprising many of the leading US institutional investors in the biotech and healthcare field.
Dr McColl said: "Viralytics' profile among US institutional healthcare investors is rapidly ascending. These are both very significant conferences in which we will outline recent accomplishments and the company's strategic pathway. Following our successful capital raise we now have an impressive base of international institutional investors."
The presentation from Dr McColl will highlight recent developments and future clinical and business plans including:
- The completion of the transformational capital raising of A$27M mainly from international healthcare institution
- Success in achieving the primary endpoint in the US Phase 2 CALM melanoma clinical trial
- CAVATAK™'s activity in injected and metastatic (secondary) tumours with good tolerability in late stage melanoma patients
- Initiation of the STORM Phase 1/2 intravenous UK trial in solid cancer patients
- Planning for a randomized Phase 2 melanoma trial
- Recent commercial activity in the field of cancer immunotherapy
Enquiries:
Dr Malcolm McColl |
Rudi Michelson |
Chief Executive Officer |
Monsoon Communications |
02 9988 4000 |
03 9620 3333 |
About Viralytics Ltd:
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells provides the potential for low toxicity in the patient.
The company has fully enrolled a phase 2 clinical trial of intratumourally administeredCAVATAK™ in the treatment ofLate stageMelanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (SystemicTreatmentOfResistantMalignancies) study, will enrol patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.
Viralytics is developing oncolytic immunotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and metastatic cancer cells through cell lysis and the potential generation of an immune response against the cancer cells. Together this mechanism of action is known as oncolytic immunotherapy. CAVATAK™'s preferential targeting of cancer cells provides the potential for low toxicity in the patient.
The company has fully enrolled a phase 2 clinical trial of intratumourally administeredCAVATAK™ in the treatment ofLate stageMelanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics has commenced a Phase 1/2 trial of CAVATAK™ delivered systemically (intravenously). This trial, referred to as the STORM (SystemicTreatmentOfResistantMalignancies) study, will enrol patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. The STORM trial is being conducted at three UK cancer centres.
Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under VRACY on the US OTCQX International market.
|
distributed by
|
